AMT Plans to Reduce Workforce by Half to 45 Full-Time Employees

Amsterdam Molecular Therapeutics (AMT) NV plans to cut its workforce by half to 45 full-time employees and suspended the development program of its main product Glybera as further investment is no longer tenable, the company said in a statement today on its website.

To contact the editor responsible for this story: Fred Pals at fpals@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.